SBIR/STTR Research Award

IMAGING OF APOPTOSIS

Award identifier 2e2ef8fde73e4b20610f5ad894b105013d699c092225c4d6603054123b99585aAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,975,225

Program and phase

SBIR · Phase II

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MOLECULAR THERAPEUTICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The goal of this Phase II project is to continue development of a novel molecular imaging reporter construct that can report induction of apoptosis in intact cells and animals. Under normal biological conditions a tight balance between proliferation and cell death (apoptosis) is essential. An imbalance in these two opposing processes has been implicated in a variety of diseases which includes neurdegenerative disorders (e.g. Alzheimer's disease), myelodysplastic syndromes, AIDS, ischemic injury, autoimmune disease and cancer. The ability to quantitatively detect (image) apoptosis is a significant advancement for its use in high-throughput screening and validation of novel therapeutic molecules for the above diseases. During the Phase I award period, we have developed and validated a novel molecular reporter cassette which when transfected into mammalian cells results in a polypeptide that has significantly attenuated levels of reporter activity. If the cefl undergoes apoptosis, a caspase (a protease activated during apoptosis) specific cleavage of the reporter protein occurs which activates the reporter enabling detectionhmaging of the apoptotic event. In this Phase II proposal, we will test the specifity of this approach to image three different proteases involved in apoptosis (Caspase-3, -8 and -9). Three different reporter molecules, each containing a different cleavage site specific for one of three Caspases will be constituatively expressed in D54 human glioma cells with either luciferase (for bioluminescence detection) or green fluorescent protein (for fluorescence detection) as the activatable reporter (Specific Aim 1). These cell lines will be used to evaluate the specificity and sensitivity of these reporter molecules to "report" on specific Caspases activated during different anticancer therapies. Moreover, in Specific Aim 2 transgenic mice will be developed using these reporter molecules wherein the activation of apoptosis within the skin in response to UV radiation can be imaged. Overall, this reporter molecule will provide a unique opportunity to image specific apoptotic events non-invasively and in real time in intact cell and animals. This feature will provide exciting and important opportunities for both the pharmaceutical industry and scientists to study apoptosis using in vitro high throughput screening compounds with pro- and anti- apoptotic activity as well as for target validation in vivo in intact animals.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.